Autolus Therapeutics (AUTL) Earnings Date & Reports
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer... Show more
AUTL is expected to report earnings to rise 188.44% to -25 cents per share on May 01
Q1'25
Est.
$-0.26
Q4'24
Beat
by $0.12
Q3'24
Missed
by $0.10
Q2'24
Missed
by $0.03
Q1'24
Missed
by $0.16
The last earnings report on March 20 showed earnings per share of -9 cents, beating the estimate of -20 cents. With 1.14M shares outstanding, the current market capitalization sits at 441.77M.